Publikationen in Zusammenarbeit mit Forschern von Hospital de la Santa Creu i Sant Pau (30)

2023

  1. Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions

    Journal of Clinical Virology, Vol. 167

  2. Susceptibility to hepatitis B virus infection in adults living in Spain

    Liver International, Vol. 43, Núm. 5, pp. 1015-1020

  3. The slowdown of new infections by human retroviruses has reached a plateau in Spain

    Journal of Medical Virology, Vol. 95, Núm. 5

2022

  1. Late presentation of human T-lymphotropic virus type 1 infection in Spain reflects suboptimal testing strategies: on behalf of the Human T-lymphotropic Virus (HTLV) Spanish Network

    International Journal of Infectious Diseases, Vol. 122, pp. 970-975

2019

  1. Clinical presentation of individuals with human T-cell leukemia virus type-1 infection in Spain

    Open Forum Infectious Diseases, Vol. 6, Núm. 2

2017

  1. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 7, pp. 2083-2088

  2. HIV type 2 epidemic in Spain: Challenges and missing opportunities

    AIDS, Vol. 31, Núm. 10, pp. 1353-1364

  3. Human T-lymphotropic virus type 1 infection and disease in Spain

    AIDS, Vol. 31, Núm. 12, pp. 1653-1663

  4. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

2015

  1. Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV

    AIDS, Vol. 29, Núm. 5, pp. 571-581

  2. IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection

    AIDS

  3. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2014

  1. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study

    BMC Nephrology, Vol. 15, Núm. 1

  2. IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians

    PLoS ONE, Vol. 9, Núm. 4

2011

  1. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study)

    HIV Medicine, Vol. 12, Núm. 6, pp. 374-382

  2. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: The ARTEN Trial

    Antiviral Therapy, Vol. 16, Núm. 3, pp. 339-348

2010

  1. Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C

    AIDS Research and Human Retroviruses, Vol. 26, Núm. 4, pp. 419-424

2009

  1. (Enfermedades Infecciosas y Microbiologia Clinica (2009) 27, 4, (222-235))

    Enfermedades Infecciosas y Microbiologia Clinica

2007

  1. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients

    Journal of Viral Hepatitis, Vol. 14, Núm. 6, pp. 387-391